In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Express Scripts pays $4.7bn for WellPoint's NextRx business

Executive Summary

Express Scripts announced it will acquire health plan administrator WellPoint's three NextRx pharmacy benefit management subsidiaries--NextRx Inc., NextRx Services Inc., and NextRx LLC--for $4.7bn, or approximately $3.3bn cash plus $1.4bn in Express common stock (based on the market average, this could mean about 29.4mm shares). Express is financing the transaction using money from a debt sale.
Deal Industry
  • Pharmaceuticals
  • Services
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies